

The logo for Seeking Alpha, with the text 'Seeking Alpha' in white and a yellow Greek letter alpha symbol to the right, all on a dark red background.

## EPIX Pharmaceuticals Inc. Q4 2007 Earnings Call Transcript

### Question-and-Answer Session

---

**Operator**

Thank you. (Operator Instructions)

And your first question comes from the line of Ted Tenthoff with Piper Jaffray.

**Ted Tenthoff - Piper Jaffray**

Great. Thank you very much. Can you hear me at here Michael?

**Michael Kauffman**

We can.

**Ted Tenthoff - Piper Jaffray**

Great. How are you?

**Michael Kauffman**

Good.

**Ted Tenthoff - Piper Jaffray**

Two quick questions, one just a little housekeeping. Kim, I didn't hear what was the net loss guidance for the year? And then, Michael, if you can, you went into a little bit of detail about the Phase 2b that you'll be starting this year in Alzheimer's disease in the first half, can give us a little bit more color on what you might be doing in terms of size of that trial, will that be an international trial? What's your current thinking on the kind of next steps there?

**Kim Drapkin**

Okay. Ted, thank you for your questions. The net loss guidance for 2008 is \$45 million to \$50 million.

**Ted Tenthoff - Piper Jaffray**

Okay. Great. Thank you.

**Kim Drapkin**

Michael?

**Michael Kauffman**

Sure. Ted, on the question of the Alzheimer's program, which we're working with Glaxo to design. This is a program given the data that we received, obtained in the Phase 2a, there is interest on both sides in looking at both monotherapy and in combination therapy moving ahead. So, we haven't finalized the program yet, but our expecting is, is that there are likely to be two trials. The length of the trials will be on the order of 12 weeks, possibly longer, possibly 12 weeks for the monotherapy and possibly longer for the combination study.

The combination study will be carried out with our drug in combination with Aricept, as compared to Aricept alone. And the monotherapy study is for patients who are naïve to cognitive therapy. The plan is that as we stand now that the trials will be conducted in United States.

**Ted Tenthoff - Piper Jaffray**

Great. That's very helpful. Good luck with that.

**Michael Kauffman**

Thank you.

**Kim Drapkin**

Thanks, Ted.

**Operator**

And your next question comes from the line of Alan Carr with Needham.

**Alan Carr - Needham & Company**

Hi, good morning, everyone.

**Kim Drapkin**

Good morning, Alan.

**Alan Carr - Needham & Company**

I was wondering if you could give us a little more information about the plans for 7034 and I recall that you were going to explore one of the enantiomers in obesity. So could you go through over your thought process behind the plans for 2008 with this drug?

Copyright © 2008 CNET Networks, Inc. All Rights Reserved.